Showing results (171-180 of 179) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 179 results.
Oncoimmunology|September 14, 2016
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancerLauren V Wood, Antonio Fojo, Brenda D Roberson, et al.
The Oncologist|May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate CancerRavi A Madan, Marijo Bilusic, Mark N Stein, et al.
Cancer Immunology, Immunotherapy : CII|November 6, 2009
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerJames L Gulley, Philip M Arlen, Ravi A Madan, et al.
Journal for Immunotherapy of Cancer|March 5, 2021
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancerRavi A Madan, Fatima Karzai, Renee N Donahue, et al.
Clinical Genitourinary Cancer|June 23, 2016
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial CarcinomaAndrea B Apolo, Fatima H Karzai, Jane B Trepel, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 29, 2023
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumorsChristopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
BJU International|September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design ConsiderationsDavid J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.
Pageof 18